Nostrum Pharmaceuticals LLC v. FDA

How courts have described this case

Verbatim parenthetical descriptions written by other courts when citing this decision. Ranked by citation-network relevance.

• stating that “our review [under Section 505(h)] is limited to final rejections of drug applications, not interim decisions or nonbinding statements subject to further [agency] review or change”

Source: CourtListener parenthetical corpus (CC0).

Cited by

3 cases in this archive cite this case.

• Avadel Cns Pharmaceuticals, LLC v. Becerra
  District of Columbia· 2022-11-03
• Sorrento Therapeutics, Inc. v. Anthony Mack
  Court of Chancery of Delaware· 2023-09-01
• An opinion was released in case 23-5200, Vanda Pharmaceuticals, Inc. v. FDA
  D.C. Circuit· 2024-12-17

Cites

5 cases in this archive are cited by this case.

• Bennett v. Spear
  Supreme Court· 1997-03-19· cited 3,786×
• Bellsouth Corp. v. Federal Communications Commission
  D.C. Circuit· 1994-03-15· cited 34×
• Cal. Cmty. Against Toxics v. Envtl. Prot. Agency
  D.C. Circuit· 2019-08-20· cited 33×
• MediNatura, Inc. v. FDA
  D.C. Circuit· 2021-05-28· cited 18×
• Pharmaceutical Manufacturing Research Services, Inc. v. FDA
  D.C. Circuit· 2020-05-01· cited 10×